Virtual Symposium - Assessing the Role of TAVR Across the Risk Continuum: Emerging Evidence, Evolving Guidance, and Expert Perspectives
Aortic stenosis (AS) is a fatal disease if not treated promptly, especially in the older population. There is a need of multidisciplinary team approach for the comprehensive diagnosis, staging, risk stratification and treatment involving patient preferences, in order to optimize the management of this insidious disease. Studies have suggested that TAVR can be used as an alternative for SVAR in high risk as well as low risk patients with severe AS. Additionally, guidelines have underlined the benefits of TAVR with many terms and conditions. The choice of intervention for a patient with severe AS should be a shared decision making process that involves the lifetime benefits as well as risk associated with the therapy. This educational activity will help clinicians not only with screening and staging based on updated guidelines, but with choosing the best treatment option in this setting.
US-based healthcare professionals, including primary care clinicians (PCPs), interventional cardiologists, cardiologists, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Determine the prevalence and clinical significance of severe aortic stenosis.
- Outline strategies to screen, diagnose, and risk stratify patients with aortic stenosis as a means to identify patient candidates who may benefit from TAVR treatment.
- Summarize the updated guidelines and evidence from recent clinical trials and real-world studies of TAVR vs. SAVR in AS patients across the risk continuum
- Develop individualized treatment plans for patients with severe aortic stenosis based on updated evidence, guidelines, and patient-specific clinical presentation and needs
Deepak L. Bhatt, MD, MPH (Chair)
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Professor of Medicine, Harvard Medical School
Dr. Bhatt discloses the following:
Contracted Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, MyoKardia, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, The Medicines Company
Angela Lowenstern, MD, MHSc
Assistant Professor of Medicine
Vanderbilt University Medical Center
Dr. Lowenstern discloses the following:
Consulting Fees: Edwards Lifesciences
Gilbert H. Tang, MD, MSc, MBA, FACC, FSCAI
Associate Professor of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai
Surgical Director, Structural Heart Program, Mount Sinai Health System
New York, NY
Dr. Tang discloses the following:
Consulting Fees: Medtronic, Abbott Structural Heart, NeoChord, JenaValve
Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Medtronic, Abbott Structural Heart
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported in part by educational grants from Medtronic and Edwards Lifesciences LLC.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-302-H01-P
For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor within 4-6 weeks. Pharmacists have up to thirty (30) days from the live event to complete the evaluation and claim credit.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING DIETICIAN EDUCATION
This program offers 1.0 CPEUs for dieticians.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners and Managers
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period July 27, 2022 through July 27, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.